RNA

Total RNA was prepared from cell line WM3918. WM3918 is a metastatic human melanoma cell line. These cells need 5-10% of FBS to adhere to culture flask. This cell line expresses wild type BRAF, N-RAS, c-KIT, and CDK4 genes. WM3918 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3918. WM3918 is a metastatic human melanoma cell line. These cells need 5-10% of FBS to adhere to culture flask. This cell line expresses wild type BRAF, N-RAS, c-KIT, and CDK4 genes. WM3918 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3928. WM3928 is a human metastatic melanoma cell line that displays a mesenchymal morphology. This cell line was established from a left inguinal lymph node metastatic site of a patient. This cell line contains the PTEN Y177X substitution mutation. Y177 is a phosphorylation site in PTEN and mutation of Y177 leads to misregulation of PTEN function. This cell line contains wild type BRAF, N-RAS, c-KIT and CDK4 genes. WM3928 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3928. WM3928 is a human metastatic melanoma cell line that displays a mesenchymal morphology. This cell line was established from a left inguinal lymph node metastatic site of a patient. This cell line contains the PTEN Y177X substitution mutation. Y177 is a phosphorylation site in PTEN and mutation of Y177 leads to misregulation of PTEN function. This cell line contains wild type BRAF, N-RAS, c-KIT and CDK4 genes. WM3928 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3928. WM3928 is a human metastatic melanoma cell line that displays a mesenchymal morphology. This cell line was established from a left inguinal lymph node metastatic site of a patient. This cell line contains the PTEN Y177X substitution mutation. Y177 is a phosphorylation site in PTEN and mutation of Y177 leads to misregulation of PTEN function. This cell line contains wild type BRAF, N-RAS, c-KIT and CDK4 genes. WM3928 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM4002. WM4002 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including hemizygous deletion and is wild type for N-RAS, c-KIT, and CDK4 genes. WM4002 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM4002. WM4002 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including hemizygous deletion and is wild type for N-RAS, c-KIT, and CDK4 genes. WM4002 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM4002. WM4002 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including hemizygous deletion and is wild type for N-RAS, c-KIT, and CDK4 genes. WM4002 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM46. WM46 is a metastatic human melanoma cell line that displays a pigmented fibroblastic morphology. This cell line was established from left chest & abdomen in a 43-year-old female patient with level IV superficial spreading melanoma and a tumor thickness of 1.44. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line expresses PTEN loss of function including hemizygous deletion, and R24C mutation at position 24 in the CDK4 gene. The R24C mutation results in an amino acid substitution at codon 24 in CDK4, from an arginine (R) to cysteine (C). This mutation abolishes the ability of CDK4 to bind to p16(INK4a). WM46 cells produce xenograft tumors when injected into immunocompromised mice.